Page last updated: 2024-11-04

3,5-diiodothyronine, (l)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID92859
CHEMBL ID1877304
CHEBI ID94696
SCHEMBL ID445767
MeSH IDM0318693

Synonyms (44)

Synonym
3,5-diiodo-l-thyronine
1041-01-6
SPECTRUM5_001995
D1119
NCGC00163110-01
(2s)-2-azaniumyl-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoate
(2s)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
A800898
bdbm50431468
l-tyrosine, o-(4-hydroxyphenyl)-3,5-diiodo-
cal3mrm51f ,
alanine, 3-(4-(p-hydroxyphenoxy)-3,5-diiodophenyl)-, l-
einecs 213-867-7
nsc 90469
3,5-diiodothyronine, l-
3,5-diiodothyronine (van)
unii-cal3mrm51f
CHEMBL1877304 ,
3-[4-(p-hydroxyphenoxy)-3,5-diiodophenyl]-l-alanine
o-(4-hydroxyphenyl)-3,5-diiodo-l-tyrosine
l-t2
AKOS015900357
liothyronine sodium impurity e [ep impurity]
l-diiodothyronine
3,5-diiodothyronine l(+)-form [mi]
(2s)-2-amino-3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoic acid
(+)-diiodothyronine
levothyroxine sodium impurity e [ep impurity]
S6474
BRD-K65411918-001-01-5
SCHEMBL445767
Q-200349
DS-2181
(s)-2-amino-3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoic acid
mfcd00064987
AC-8874
CHEBI:94696
(2s)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid (diiodothyronine)
Q27166500
o-(4-hydroxyphenyl)3,5-diiodo-l-tyrosine
DTXSID801016529
3,5-diiodo-thyronine
3,5-t2; nsc 90469; (2s)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
3,5-diiodo-l-thyronine (3,5-t2)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency8.43680.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proliferating cell nuclear antigenHomo sapiens (human)IC50 (µMol)6.30003.60004.95006.3000AID739861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIProliferating cell nuclear antigenHomo sapiens (human)
base-excision repair, gap-fillingProliferating cell nuclear antigenHomo sapiens (human)
mismatch repairProliferating cell nuclear antigenHomo sapiens (human)
heart developmentProliferating cell nuclear antigenHomo sapiens (human)
translesion synthesisProliferating cell nuclear antigenHomo sapiens (human)
epithelial cell differentiationProliferating cell nuclear antigenHomo sapiens (human)
replication fork processingProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of deoxyribonuclease activityProliferating cell nuclear antigenHomo sapiens (human)
response to estradiolProliferating cell nuclear antigenHomo sapiens (human)
cellular response to UVProliferating cell nuclear antigenHomo sapiens (human)
estrous cycleProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA repairProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA replicationProliferating cell nuclear antigenHomo sapiens (human)
response to cadmium ionProliferating cell nuclear antigenHomo sapiens (human)
cellular response to hydrogen peroxideProliferating cell nuclear antigenHomo sapiens (human)
cellular response to xenobiotic stimulusProliferating cell nuclear antigenHomo sapiens (human)
response to dexamethasoneProliferating cell nuclear antigenHomo sapiens (human)
liver regenerationProliferating cell nuclear antigenHomo sapiens (human)
positive regulation of DNA-directed DNA polymerase activityProliferating cell nuclear antigenHomo sapiens (human)
response to L-glutamateProliferating cell nuclear antigenHomo sapiens (human)
mitotic telomere maintenance via semi-conservative replicationProliferating cell nuclear antigenHomo sapiens (human)
leading strand elongationProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
purine-specific mismatch base pair DNA N-glycosylase activityProliferating cell nuclear antigenHomo sapiens (human)
chromatin bindingProliferating cell nuclear antigenHomo sapiens (human)
damaged DNA bindingProliferating cell nuclear antigenHomo sapiens (human)
protein bindingProliferating cell nuclear antigenHomo sapiens (human)
enzyme bindingProliferating cell nuclear antigenHomo sapiens (human)
nuclear estrogen receptor bindingProliferating cell nuclear antigenHomo sapiens (human)
receptor tyrosine kinase bindingProliferating cell nuclear antigenHomo sapiens (human)
dinucleotide insertion or deletion bindingProliferating cell nuclear antigenHomo sapiens (human)
MutLalpha complex bindingProliferating cell nuclear antigenHomo sapiens (human)
histone acetyltransferase bindingProliferating cell nuclear antigenHomo sapiens (human)
identical protein bindingProliferating cell nuclear antigenHomo sapiens (human)
protein-containing complex bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase bindingProliferating cell nuclear antigenHomo sapiens (human)
DNA polymerase processivity factor activityProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionProliferating cell nuclear antigenHomo sapiens (human)
male germ cell nucleusProliferating cell nuclear antigenHomo sapiens (human)
nucleusProliferating cell nuclear antigenHomo sapiens (human)
nuclear laminaProliferating cell nuclear antigenHomo sapiens (human)
nucleoplasmProliferating cell nuclear antigenHomo sapiens (human)
replication forkProliferating cell nuclear antigenHomo sapiens (human)
centrosomeProliferating cell nuclear antigenHomo sapiens (human)
nuclear bodyProliferating cell nuclear antigenHomo sapiens (human)
nuclear replication forkProliferating cell nuclear antigenHomo sapiens (human)
PCNA complexProliferating cell nuclear antigenHomo sapiens (human)
extracellular exosomeProliferating cell nuclear antigenHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexProliferating cell nuclear antigenHomo sapiens (human)
chromatinProliferating cell nuclear antigenHomo sapiens (human)
replisomeProliferating cell nuclear antigenHomo sapiens (human)
PCNA-p21 complexProliferating cell nuclear antigenHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID208543Relative binding affinity towards T3 nuclear receptor in rat heart, expressed as percent ratio of IC50 for T3 to that of compound1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID1149270Thyroxine-like activity in rat by antigoiter assay relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson Analysis.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1668530Agonist activity at recombinant human pFA-CMV fused PPARgamma expressed in HEK293T cells transfected with pFR-luciferase plasmid and pRL-SV40 plasmid at 10 uM incubated for 14 to 16 hrs by dual glo luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARĪ³.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID26068pKa for compound was evaluated1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID195675Thyromimetic activity (induction of GPDH) in rat liver expressed as percentage of ratio of the ED50 for T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID195669Thyromimetic activity (induction of GPDH) in rat heart expressed as percentage of ratio of the ED50 for T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID208544Relative binding affinity for T3 thyroid hormone nuclear receptor in rat liver, expressed as percent ratio of IC50 compared to T31988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Thyroid hormone analogues. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart.
AID739861Inhibition of human recombinant PCNA interaction with PIP box protein N-5-carboxyfluorescein-SAVLQKKITDYFHPKK after 30 mins by fluorescence polarization assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]